Amundi SA (AMUN)
Euronext Paris · France · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 89.70 |
|---|---|
| 52-week range | 60.90 – 97.70 |
| Return, 1 month / 3 months | −1.7% / +1.2% |
| Return, 1 year / 3 years | +41.3% / +118.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 51 |
| Volatility (1 year) | 21.9% |
| Worst drawdown (1 year) | -12.0% |
| Average daily value traded | 14.33M EUR |
| Dividend yield | 4.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Amundi is a French asset management firm based in Paris. It manages investment funds and portfolios for individual savers, institutional investors and corporate clients, offering services that include mutual funds, index-tracking funds and discretionary portfolio management. Its business spans asset classes such as equities, bonds and money market instruments, and it serves customers in France and across international markets through a network of offices and distribution partners.
Amundi SA trades under the code AMUN on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Amundi SA (AMUN) trades on the Euronext Paris in France. It last closed at EUR 89.70 on 27 October 2026.
Its price-based Market X-Ray is 87 out of 100 (a strong price profile), ranking 5 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 41.3% and over the last three months it rose 1.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.9% | ||
| From 52-week high | -8.0% | ||
| Momentum | 87 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 1.2% | ||
| 6-month return | 23.3% | ||
| 12-month return, skipping the last month | 43.8% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -12.0% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 14.33M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | −1.7% |
| 3 months | +1.2% |
| 6 months | +23.3% |
| 1 year | +41.3% |
| 3 years | +118.4% |
| 5 years | +57.9% |
Signals
| 50-day / 200-day average | 91.58 / 82.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jun 2026 | EUR 4.2500 |
| 10 Jun 2025 | EUR 4.2500 |
| 3 Jun 2024 | EUR 4.1000 |
| 22 May 2023 | EUR 4.1000 |
| 23 May 2022 | EUR 4.1000 |
| 13 May 2021 | EUR 2.9000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.